Valneva reports nine-month results
by
Contributor since / Followers
Contributor since / Followers
2 weeks ago
- Valneva press release (NASDAQ:VALN): nine-month net profit of €24.7 million
- Revenue of $116.6M.
-
Full-year 2024 Financial Guidance Narrowed
- Expected total product sales according to guidance between €160 million to €170 million and currently anticipated total revenues between €170 million and €180 million
- Expected R&D investments between €65 million and €75 million
- Expected Other income between €100 million and €110 million, including €95 million from the PRV sale
- Launch of the world’s first chikungunya vaccine in Canada and Europe underway; Further potential approvals expected in Brazil (Q4 2024) and the UK (Q1 2025);